Innovative, collaborative and well-resourced, Wilmer researchers continue to lead the way in the bold quest to cure blinding eye disease.

The combination of biomaterials engineering and AI-driven drug design offers promising solutions to some of the most pressing challenges in eye care.

Investigating molecular pathways that promote cell survival and regeneration — with the goal of preventing AMD before it begins.

New findings help explain why diabetic patients who start glucose control or have high glycemic variability may experience worsening of diabetic eye disease — and suggest a path to prevention.

Wilmer researchers and clinicians are working with The Johns Hopkins University and oversight committees to create companies to bring their treatments to market.

For a century, Wilmer researchers have driven groundbreaking advances in ophthalmology, from earlier diagnoses and revolutionary treatments to transformational patient outcomes.

After undergoing routine eye surgery, Laura Styles developed mysterious symptoms that sent Wilmer clinician-scientists on the hunt for answers that would restore her vision.

From Baltimore to Southeast Asia, Wilmer clinicians are leading groundbreaking initiatives to address critical needs in both developed and underserved regions.

An innovative Wilmer program supports promising young faculty members to explore exciting new research.

Throughout its 100-year history, Wilmer has provided one of the nation's top ophthalmology training programs, renowned for the quality of its faculty mentors.

With support from Wilmer’s Rising Professorship Program, these young researchers are working to advance high tech imaging, AI in ophthalmology, and rehabilitation for patients with low vision.